evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 3 · 42.9%Moderate 1 · 14.3%High 1 · 14.3%

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (high certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Proportion of participants switched to another biologic due to loss of response · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants switched to another biologic due to loss… compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with minimal radiographic progression compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review